| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H21N5O3 |
| Molecular Weight | 403.4338 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=NC=NC(N3CC[C@H](C3)OC4=CN=C5C=CC=CC5=N4)=C2C=C1OC
InChI
InChIKey=UBIIFKJMNRPNMT-CQSZACIVSA-N
InChI=1S/C22H21N5O3/c1-28-19-9-15-18(10-20(19)29-2)24-13-25-22(15)27-8-7-14(12-27)30-21-11-23-16-5-3-4-6-17(16)26-21/h3-6,9-11,13-14H,7-8,12H2,1-2H3/t14-/m1/s1
| Molecular Formula | C22H21N5O3 |
| Molecular Weight | 403.4338 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
PQ-10 belongs to the same class as the PDE10 inhibitor papaverine, but IC50 literature suggests that is about 5 times more potent then papaverine, yet still about 10 times less potent the known PDE10 inhibitors TP- 10 and MP-10. Preclinical development is ongoing in USA for the treatment of psychotic disorders.
